The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC, Steinberg GD.
J Urol. 2001 Mar;165(3):745-56.
PMID:11176460
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas.
Paner GP, Kamat A, Netto GJ, Samaratunga H, Varma M, Bubendorf L, van der Kwast TH, Cheng L; Members of the ISUP Bladder Tumor Consensus Panel.
Am J Surg Pathol. 2024 Jan 1;48(1):e11-e23. doi: 10.1097/PAS.0000000000002077. Epub 2023 Jun 29.
PMID:37382156
Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy.
Subiela JD, Rodríguez Faba Ó, Aumatell J, Calderón J, Mercadé A, Balañà J, Esquinas C, Algaba F, Breda A, Palou J.
BJU Int. 2022 Apr;129(4):542-550. doi: 10.1111/bju.15567. Epub 2021 Aug 23.
Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis.
Mixed Adenocarcinomatous and Neuroendocrine Tumor of the Urinary Bladder With Concomitant Carcinoma In Situ: A Case Report With a Comprehensive Immunohistochemical Analysis and Review of the Literature.
Tränkenschuh W, Biesdorf AS, Papadimas N, Samara S, Hefty R, Stahl PR.